+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

United States Diabetes Market, Size, Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

  • PDF Icon

    Report

  • 125 Pages
  • January 2023
  • Region: United States
  • Renub Research
  • ID: 5715839

United States Diabetes Market was US$ 23.32 Billion in 2022

United States Diabetes Market is expected to reach US$ 28.27 Billion by 2028, according to the publisher. In the United States, Diabetes is the 7th leading cause of death. Diabetes is a persistent disease that happens either when the pancreas has not produced enough insulin or when the body cannot effectively and efficiently uses its insulin. In the United States, cases of diabetes have risen dramatically during the last two decades, a fact driven by the increased prevalence of obesity and lifestyle changes. Diabetes ranks among the fast-growing chronic diseases in the United States. About 1.75 Million U.S. citizens are diagnosed with diabetes every year. Diabetes and pre-diabetes are leading public health concerns across the United States. About 37.3 Million Americans have diabetes, according to the CDC.



United States Diabetes Population is expected to grow with a CAGR of 3.26% from 2022 to 2028

According to CDC, 11.3% of the U.S. population has diabetes. There are mainly two types of diabetes: type 1 and type 2. A lack of insulin production characterizes type 1 diabetes, and Type 2 diabetes is caused by the body’s ineffective use of insulin. Type 2 is typically progressive and develops in people over age 45, but there are more and more children, teenagers, and young adults who are also developing diabetes.

It often results from excess physical inactivity and body weight. Higher than 1 in 10 adults in the United States live with type 1 or 2 diabetes. Type 2 diabetes accounts for approx 90% to 95% of all diagnosed cases of diabetes; type 1 diabetes accounts for about 5-10%. Approx. 283,000 Americans under age 20 are estimated to have been diagnosed with diabetes, nearly 0.35% of that population, according to American Diabetes Association.

Although, over time, diabetes can damage the heart, blood vessels, eyes, kidneys, and nerves and increase the risk of heart disease and stroke. Such damage can result in reduced blood and nerve damage. Type 2 diabetes is a significant public health problem in the USA, affecting over 12% of American adults and imposing considerable health and economic burden on individuals and society. In the United States, 96 million adults, more than 1 in 3, have pre-diabetes.

Growing Number of Diabetic Patients in the United States will create more demand for Insulin Market

Based on devices, United State Diabetes Market is classified into four types: Glucose Monitoring (CGM), Self-Monitoring Blood Glucose (SMBG), Insulin Pen, and Insulin Pump. SMBG Capturing the maximum share during the forecast period due to monitoring blood glucose (SMBG) can be valuable in managing diabetes mellitus. Patients with diabetes often measure their blood glucose to detect hypoglycemia and adjust insulin doses as needed.

The primary growth factors include the rising diabetic population, increasing awareness among the diabetes population, increasing spending on healthcare, active reimbursement policies, and technological advancement aimed at minimal and non-invasive testing methods, which significantly boost the market.

Besides, CGM and Insulin Pens will also dominate the market revenue of the United States during the upcoming year. CGM device is a tool that measures patients glucose levels 24 hours a day. However, Insulin pens offer the advantage of ease of administration, especially for patients with visual and dexterity issues, accuracy when administering small doses, convenience, and reduced pain. Today, about 59% of patients with diabetes use insulin pens in the U.S.

United States Diabetes Market was US$ 23.32 Billion in 2022

Most of the cost of diabetes care in the U.S, is provided by government insurance (including Medicare, Medicaid, and the military). The increasing diabetes prevalence has led the Government of the U.S. to launch diabetes prevention programs, raise awareness about its symptoms and encourage healthier lifestyle behavior among the citizens. However, technological developments in diabetes devices, such as the introduction of a high-end insulin pump and pens, propel the demand for these products, leading manufacturers to focus on technological innovations and developing advanced products which boost the market.

The U.S. Diabetes Prevention Program (DPP) clinical sequent translational studies have demonstrated that intensive lifestyle interventions focused on achieving 7% weight loss and at least 150 min per week of moderate physical activity can cut the risk of developing diabetes in half. Such interventions also improve health-related quality of life and enable some patients to reduce the need for medication.

Key Companies Analysis

The United States diabetes market is moderately fragmented, with few significant and generic players. The major players are B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickinson (B.D.), Novo Nordisk, Ypsomed AG, Medtronic, Insulet Corporations, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care.

In March 2022, Dexcom released G7 first in the U.K. and will expand the launch across Europe throughout 2022. Meanwhile, the CGM system is currently under review by the Food and Drug Administration for an eventual U.S. release.

In June 2022, continuous glucose monitors (CGM) were adopted among people with type 2 diabetes (T2D). However, up to 70% of CGM use is for type 1 diabetes (T1D); only 3-4% of the U.S. T2D population use CGM despite established benefits as per One Drop.

The report titled “United States Diabetes Market & Volume Forecast by SMBG (Test Strips Market and Forecast, Lancet Market and Forecast, Meter Market and Forecast, Blood Glucose (SMBG) Users and Blood Glucose Devices Reimbursement), CGM (Glucose Sensor Market Forecast, CGM Transmitter Market & Forecast, CGM User and CGM Reimbursement, Insulin Pen (Disposable Insulin Pen, Reusable Insulin Pen, Smart Insulin Pen, Insulin Pen Needle Market ,Insulin Pen Users and Reimbursement Policies), Insulin Pump (Insulin Pump Market, Insulin Pump Users, Insulin Pump Products and Reimbursement Policies), Company Analysis (B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickinson (B.D.), Novo Nordisk, Ypsomed AG, Medtronic, Insulet Corporations, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care)’’ provides a detailed analysis of Diabetes Market in the United States.

Segments Market based on Devices

1. Continuous Glucose Monitoring (CGM)
2. Self-Monitoring Blood Glucose (SMBG)
3. Insulin Pen
4. Insulin Pump

United States Diabetes Sub-Segment Analysis

1. Continuous Glucose Monitoring (CGM) - United State Food Market breakup from four viewpoints

1. Glucose Sensor Market & Forecast
2. CGM Transmitter Market & Forecast
3. CGM User
4. CGM Reimbursement

2. SMBG - United State Food Market breakup from five viewpoints

1. Test Strips Market and Forecast
2. Lancet Market and Forecast
3. Meter Market and Forecast
4. Blood Glucose (SMBG) Users
5. Blood Glucose Devices Reimbursement

3. Insulin Pen Market - United State Food Market breakup from six viewpoints

1. Disposable Insulin Pen
2. Reusable Insulin Pen
3. Smart Insulin Pen
4. Insulin Pen Needle Market
5. Insulin Pen Users
6. Reimbursement Policies

4. Insulin Pump Market - United State Food Market breakup from four viewpoints

1. Insulin Pump Market
2. Insulin Pump Users
3. Insulin Pump Products
4. Reimbursement Policies

All the 13 Companies Studied in the Report have been Studied from 3 Points

  • Company Overview
  • Recent Developments
  • Financial Insight

Company Analysis

1. B. Braun Melsungen AG
2. Eli Lilly and Company
3. Terumo Corporation
4. Becton, Dickinson (B.D.)
5. Novo Nordisk
6. Ypsomed AG
7. Medtronic
8. Insulet Corporations
9. Abbott Laboratories
10. DarioHealth Crop
11. Dexcom, Inc
12. Roche Diagnostic
13. Tandem Diabetes Care

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges

5. United States Diabetes Market

6. United States Diabetes Population & Forecast
6.1 Type 1 Diabetes
6.2 Type 2 Diabetes

7. Market Share - United States Diabetes Analysis
7.1 By Types

8. Continuous Glucose Monitoring Market (CGM) - Market & Users
8.1 CGM Market by Components
8.1.1 Glucose Sensor Market
8.1.2 CGM Transmitter Market
8.2 CGM User
8.3 Reimbursement Policies of CGM Devices in United States

9. Blood Glucose Device (SMBG) - United States Market & Users
9.1 Market
9.1.1 Type 1 (SMBG)
9.1.2 Type 2 (SMBG)
9.2 Test Strips Market
9.2.1 Type 1
9.2.2 Type 2
9.3 Lancet Market and Forecast
9.3.1 Type 1
9.3.2 Type 2
9.4 Meter Market and Forecast
9.4.1 Type 1
9.4.2 Type 2
9.5 Blood Glucose (SMBG) Users
9.5.1 Type 1
9.5.2 Type 2
9.6 Reimbursement Policies of Blood Glucose Devices in United States

10. Insulin Pen - United States Market & User
10.1 Insulin Pen Market
10.1.1 Disposable Insulin Pen
10.1.2 Reusable Insulin Pen
10.1.3 Smart Insulin Pen
10.2 Insulin Pen User
10.2.1 Disposable Insulin Pen
10.2.2 Reusable Insulin Pen
10.2.3 Smart Insulin Pen
10.3 Insulin Pen Needle Market
10.4 Reimbursement Policies of Insulin Pen in United States

11. Insulin Pump - United States Market & Users
11.1 Insulin Pump Market
11.1.1 Type 1
11.1.2 Type 2
11.2 Insulin Pump User
11.2.1 Type 1
11.2.2 Type 2
11.3 Differentiation Points of Insulin Pump Products in United States
11.3.1 Animas Vibe
11.3.2 Medtronic 530G with Enlite
11.3.3 Insulet OmniPod
11.3.4 Tandem t: slim
11.3.5 Roche Accu-Chek Combo
11.4 Training Model for Patients & HCP - of Medtronic, Animas, Insulet Corp & Tandem Diabetes Care
11.4.1 Medtronic
11.5 Insulet Corporation
11.5.1 Training Structure for New Patients - Insulet Corporation
11.6 Animas Corporation
11.6.1 Training Modules for New Patients
11.6.2 Training Modules for HCP (Health Care Professional)
11.7 Tandem Diabetes Care
11.8 Reimbursement Policies on Insulin Pump

12. Insulin Pen - Company Analysis
12.1 B. Braun Melsungen AG
12.1.1 Overview
12.1.2 Recent Development
12.1.3 Revenue
12.2 Eli Lilly
12.2.1 Overview
12.2.2 Recent Development
12.2.3 Revenue
12.3 Terumo Corporation
12.3.1 Overview
12.3.2 Recent Development
12.3.3 Revenue
12.4 BD
12.4.1 Overview
12.4.2 Recent Development
12.4.3 Revenue
12.5 Novo Nordisk A/S
12.5.1 Overview
12.5.2 Recent Development
12.5.3 Revenue
12.6 Ypsomed AG
12.6.1 Overview
12.6.2 Recent Development
12.6.3 Revenue

13. Insulin Pump - Company Analysis
13.1 Medtronic
13.1.1 Overview
13.1.2 Recent Development
13.1.3 Revenue
13.2 Insulet Corporation
13.2.1 Overview
13.2.2 Recent Development
13.2.3 Revenue

14. SMBG - Company Analysis
14.1 DarioHealth Corp
14.1.1 Overview
14.1.2 Recent Development
14.1.3 Revenue
14.2 Abbott Laboratories
14.2.1 Overview
14.2.2 Recent Development
14.2.3 Revenue

15. CGM - Company Analysis
15.1 Dexcom Inc
15.1.1 Overview
15.1.2 Recent Development
15.1.3 Revenue
15.2 Roche
15.2.1 Overview
15.2.2 Recent Development
15.2.3 Revenue
15.3 Tandem Diabetes Care
15.3.1 Overview
15.3.2 Recent Development
15.3.3 Revenue

List of Figures:
Figure 01: United States - Diabetes Market (Billion US$), 2017 - 2022
Figure 02: United States - Forecast for Diabetes Market (Billion US$), 2023 - 2028
Figure 03: United States - Type 1 Diabetes Population (Thousand), 2017 - 2022
Figure 04: United States - Forecast for Type 1 Diabetes Population (Thousand), 2023 - 2028
Figure 05: United States - Type 2 Diabetes Population (Thousand), 2017 - 2022
Figure 06: United States - Forecast for Type 2 Diabetes Population (Thousand), 2023 - 2028
Figure 07: United States - Glucose Sensor Market Market (Million US$), 2017 - 2023
Figure 08: United States - Forecast for Glucose Sensor Market Market (Million US$), 2023 - 2028
Figure 09: United States - CGM Transmitter Market Market (Million US$), 2017 - 2023
Figure 10: United States - Forecast for CGM Transmitter Market Market (Million US$), 2023 - 2028
Figure 11: United States - CGM User (Thousand), 2017 - 2023
Figure 12: United States - Forecast for CGM User (Thousand),2023 - 2028
Figure 13: United States - Self-Monitoring of Blood Glucose (SMBG) Type 1 Diabetes Market (Million US$), 2023 - 2028
Figure 14: United States - Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 1 Diabetes Market (Million US$), 2017 - 2023
Figure 15: United States - Self-Monitoring of Blood Glucose (SMBG) Type 2 Diabetes Market (Million US$), 2023 - 2028
Figure 16: United States - Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 2 Diabetes Market (Million US$), 2017 - 2023
Figure 17: United States - Test Strips Type 1 Diabetes Market (Million US$), 2023 - 2028
Figure 18: United States - Forecast for Test Strips Type 1 Diabetes Market (Million US$), 2017 - 2023
Figure 19: United States - Test Strips Type 2 Diabetes Market (Million US$), 2023 - 2028
Figure 20: United States - Forecast for Test Strips Type 2 Diabetes Market (Million US$), 2017 - 2023
Figure 21: United States - Lancet Type 1 Diabetes Market (Million US$), 2023 - 2028
Figure 22: United States - Forecast for Lancet Type 1 Diabetes Market (Million US$), 2017 - 2023
Figure 23: United States - Lancet Type 2 Diabetes Market (Million US$), 2023 - 2028
Figure 24: United States - Forecast for Lancet Type 2 Diabetes Market (Million US$), 2017 - 2023
Figure 25: United States - Meter Type 1 Diabetes Market (Million US$), 2023 - 2028
Figure 26: United States - Forecast for Meter Type 1 Diabetes Market (Million US$), 2017 - 2023
Figure 27: United States - Meter Type 2 Diabetes Market (Million US$), 2023 - 2028
Figure 28: United States - Forecast for Meter Type 2 Diabetes Market (Million US$), 2017 - 2023
Figure 29: United States - Self-Monitoring of Blood Glucose (SMBG) Type 1 Users (Thousand), 2017 - 2022
Figure 30: United States - Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 1 Users (Thousand), 2023 - 2028
Figure 31: United States - Self-Monitoring of Blood Glucose (SMBG) Type 2 Users (Thousand), 2017 - 2022
Figure 32: United States - Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 2 Users (Thousand), 2023 - 2028
Figure 33: United States - Disposable Insulin Pen Market (Million US$), 2017 - 2023
Figure 34: United States - Forecast for Disposable Insulin Pen Market (Million US$), 2023 - 2028
Figure 35: United States - Reusable Insulin Pen Market (Million US$), 2017 - 2023
Figure 36: United States - Forecast for Reusable Insulin Pen Market (Million US$), 2023 - 2028
Figure 37: United States - Smart Insulin Pen Market (Million US$), 2017 - 2023
Figure 38: United States - Forecast for Smart Insulin Pen Market (Million US$), 2023 - 2028
Figure 39: United States - Disposable Insulin Pen User (Thousand), 2017 - 2022
Figure 40: United States - Forecast for Disposable Insulin Pen User (Thousand), 2023 - 2028
Figure 41: United States - Reusable Insulin Pen User (Thousand), 2017 - 2022
Figure 42: United States - Forecast for Reusable Insulin Pen User (Thousand), 2023 - 2028
Figure 43: United States - Smart Insulin Pen User (Thousand), 2017 - 2022
Figure 44: United States - Forecast for Smart Insulin Pen User (Thousand), 2023 - 2028
Figure 45: United States - Insulin Pen Needle Market Market (Million US$), 2017 - 2023
Figure 46: United States - Forecast for Pen Needle Market for Market (Million US$), 2023 - 2028
Figure 47: United States - Insulin Pump Market for Type 1 Diabetes Market (Million US$), 2017 - 2023
Figure 48: United States - Forecast for Insulin Pump Market for Type 1 Diabetes Market (Million US$), 2023 - 2028
Figure 49: United States - Insulin Pump Market for Type 2 Diabetes Market (Million US$), 2017 - 2023
Figure 50: United States - Forecast for Insulin Pump Market for Type 2 Diabetes Market (Million US$), 2023 - 2028
Figure 51: United States - Insulin Pump Type 1 Users (Thousand), 2017 - 2022
Figure 52: United States - Forecast for Insulin Pump Type 1 Users (Thousand), 2023 - 2028
Figure 53: United States - Insulin Pump Type 2 Users (Thousand), 2017 - 2022
Figure 54: United States - Forecast for Insulin Pump Type 2 Users (Thousand), 2023 - 2028
Figure 55: B. Braun Melsungen AG - Global Revenue (Billion US$), 2017 - 2022
Figure 56: B. Braun Melsungen AG - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 57: Eli Lilly - Global Revenue (Billion US$), 2017 - 2022
Figure 58: Eli Lilly - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 59: Terumo Corporation - Global Revenue (Billion US$), 2017 - 2022
Figure 60: Terumo Corporation - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 61: BD - Global Revenue (Billion US$), 2017 - 2022
Figure 62: BD - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 63: Novo Nordisk A/S - Global Revenue (Billion US$), 2017 - 2022
Figure 64: Novo Nordisk A/S - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 65: Ypsomed AG - Global Revenue (Billion US$), 2017 - 2022
Figure 66: Ypsomed AG - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 67: Medtronic - Global Revenue (Billion US$), 2017 - 2022
Figure 68: Medtronic - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 69: Insulet Corporation - Global Revenue (Billion US$), 2017 - 2022
Figure 70: Insulet Corporation - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 71: DarioHealth Corp - Global Revenue (Billion US$), 2017 - 2022
Figure 72: DarioHealth Corp - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 73: Abbott Laboratories - Global Revenue (Billion US$), 2017 - 2022
Figure 74: Abbott Laboratories - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 75: Dexcom Inc - Global Revenue (Billion US$), 2017 - 2022
Figure 76: Dexcom Inc - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 77: Roche - Global Revenue (Billion US$), 2017 - 2022
Figure 78: Roche - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 79: Tandem Diabetes Care - Global Revenue (Billion US$), 2017 - 2022
Figure 80: Tandem Diabetes Care - Forecast for Global Revenue (Billion US$), 2023 - 2028

List of Tables:
Table 01: United States - Diabetes Market Share by Type (Percent), 2017 - 2022
Table 02: United States - Forecast for Diabetes Market Share by Type (Percent), 2023 - 2028

Companies Mentioned

  • B. Braun Melsungen AG
  • Eli Lilly and Company
  • Terumo Corporation
  • Becton, Dickinson (B.D.)
  • Novo Nordisk
  • Ypsomed AG
  • Medtronic
  • Insulet Corporations
  • Abbott Laboratories
  • DarioHealth Crop
  • Dexcom, Inc
  • Roche Diagnostic
  • Tandem Diabetes Care

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Table Information